baber/WOPTO huggingface dataset:
Patent AU-5498694-A (AU)
Title: Substituted phenyl sulfonamides as selective Beta3 agonists for the treatment of diabetes and obesity
Inventor: FISHER MICHAEL H
IPC: A61K31/403
Filed: 1994-02-08
Abstract: Substituted phenylsulphonamides having the formula: <CHEM>  where the variables are as defined in Claim 1;   are selective beta-3 adrenergic receptor agonists with very little beta-1 and beta-2 adrenergic receptor activity and as such the compounds are capable of increasing lipolysis and energy expenditure in cells. The compounds thus have very potent activity in the treatment of Type II diabetes and obesity. The compounds can also be used to reduce triglyceride levels and cholesterol levels or raise high density lipoprotein levels or to reduce gut motility. In addition, the compounds can be used to reduce neurogenic inflammation or as antidepressant agents. The compounds are prepared by coupling an aminoalkylphenylsulphonamide with an appropriately substituted alkyl epoxide. Compositions and methods for the use of the compounds in the treatment of diabetes and obesity and for reduction of triglyceride levels and cholesterol levels or raising high density lipoprotein levels or for increasing gut motility are also disclosed.
Patent AU-5501596-A (AU)
Title: Method of producing mouldings
Inventor: OVERSBERG HANS-HERMANN
IPC: B27N3/00
Filed: 1996-04-20
Abstract: PCT No. PCT/EP96/01664 Sec. 371 Date Dec. 19, 1997 Sec. 102(e) Date Dec. 19, 1997 PCT Filed Apr. 20, 1996 PCT Pub. No. WO96/33057 PCT Pub. Date Oct. 24, 1996A method of producing molded articles is provided. Raw materials that have been reduced in size are mixed together, are prepared with at least one binder, are pressed into molds, and are hardened.
Patent AU-5533194-A (AU)
Title: Activation of p53 protein
Inventor: LANE DAVID PHILIP
IPC: C07K14/245
Filed: 1993-11-26
Abstract: PCT No. PCT/GB93/02438 Sec. 371 Date Jul. 24, 1995 Sec. 102(e) Date Jul. 24, 1995 PCT Filed Nov. 26, 1993 PCT Pub. No. WO94/12202 PCT Pub. Date Jun. 9, 1994A class of mutant forms of p53 protein, such as His273 and Lys285, which are defective in conversion from the latent to the activated state by casein kinase II, but with the ability to be activated for specific DNA binding by the action of ligands such as monoclonal antibody PAb421 and heat shock protein DnaK. Activation of these mutants, which are found at high levels in certain types of tumour, can potentially lead to selective growth arrest and induction of apoptosis in the tumor cells. p53 can be constitutively activated also by deletion of the C-terminal 30 amino acids. p53 activated in this way, or by ligand binding, can be administered for the purposes of tumour or cell growth suppression.
Patent AU-5549200-A (AU)
Title: Ion mobility spectrometer
Inventor: BREACH JAMES ANDREW
IPC: G01N27/62
Filed: 2000-06-21
Abstract: An ion mobility spectrometer system comprising: an ion mobility detector; a gas/vapor circulating system for the ion mobility detector into which samples of gases and vapors of interest may be drawn for detection by the ion mobility spectrometer; the circulating system comprising an ion mobility cell, means for drying and/or cleaning the circulating gases/vapors in the circulating system, a dopant source, and means for causing circulation of the gases/vapors within the circulating system; in which the dopant source and the means for drying and/or cleaning the circulating gases/vapors are combined, whereby the need for a physically separate dopant source for the system is obviated. The dopant source material may be combined with the material for drying and or cleaning the circulating gases/vapors.
Patent AU-5556199-A (AU)
Title: Bpc-1: a secreted brain specific protein expressed and secreted by prostate and bladder cancer cells
Inventor: AFAR DANIEL E
IPC: C12N1/21
Filed: 1999-08-10
Abstract: Described is a novel gene and its encoded secreted tumor antigen, termed BPC-1, and to diagnostic and therapeutic methods and compositions useful in the management of various cancers which express BPC-1, particularly including prostate cancer and bladder cancer. In human normal tissues, BPC-1 is only expressed in certain tissues of the brain. However, BPC-1 is expressed at high levels in prostate cancer cells and is also expressed in bladder cancer cells. The structure of BPC-1 includes a signal sequence and a CUB domain. BPC-1 protein is secreted. Preliminary experimental evidence suggests that BPC-1 is directly involved in oncogenesis or maintenance of the transformed phenotype of cancer cells expressing BPC-1. BPC-1 also appears to bind specifically to a cellular protein expressed in prostate cancer cells and other cells.
Patent AU-5728296-A (AU)
Title: Method to diagnose hereditary hemochromatosis
Inventor: DRAYNA DENNIS T
IPC: C12Q1/68
Filed: 1996-05-06
Abstract: New genetic markers for the presence of a mutation in the common hereditary hemochromatosis (HH) gene are disclosed. The multiplicity of markers permits definition of genotypes characteristic of carriers and homozygotes containing this mutation in their genomic DNA.
Patent AU-5929696-A (AU)
Title: Apparatus for detecting electro-magnetic reflection from biological tissue
Inventor: FLOCK STEPHEN T
IPC: A61B5/00
Filed: 1996-05-23
Abstract: A system and method is provided to view an anatomical structure such as blood vessel in high contrast with its surrounding tissue. The system and method may be used to produce an image of an anatomical structure using reflected electromagnetic radiation singularly scattered from target tissue. The system and method may also provide same-side illumination and detection of reflected electromagnetic radiation in a convenient integral imaging device. The system and method may also provide helmet mounted imaging technology in a single integral helmet which allows the wearer to view an anatomical structure located within a patient such that the image is continuously oriented according to the orientation of the helmet wearer's head. The system and method may also be used in the performance of venipuncture. The system and method may provide for improved contrast between any anatomical structure and its surrounding tissue for use in any imaging system. <IMAGE>
Patent AU-6010198-A (AU)
Title: Aqueous dispersions of hydrophobic material
Inventor: FROLICH STEN
IPC: C08L101/00
Filed: 1998-02-03
Abstract: The invention relates to an aqueous dispersion containing a dispersant and a disperse phase containing a hydrophobic material, the dispersant comprising an anionic compound having a molecular weight less than 50,000 and being selected from carbon-containing compounds and silicon-containing compounds, and a cationic organic compound having a molecular weight less than 50,000. The invention further relates to the preparation and use of the dispersion in the production of paper. The invention also relates to a substantially water-free composition containing a hydrophobic material, an anionic compound having a molecular weight less than 50,000 and being selected from carbon-containing compounds and silicon-containing compounds, and a cationic organic compound having a molecular weight less than 50,000, as well as its use in the preparation of an aqueous dispersion.
Patent AU-6042190-A (AU)
Title: Method and apparatus for crop spraying
Inventor: BENEST ROGER
IPC: B05B1/20
Filed: 1990-07-04
Abstract: PCT No. PCT/GB90/01033 Sec. 371 Date Feb. 24, 1993 Sec. 102(e) Date Feb. 24, 1993 PCT Filed Jul. 4, 1990 PCT Pub. No. WO92/00670 PCT Pub. Date Jan. 23, 1992.A method and apparatus for spraying in relation to row crops provides downwardly extending support elements or drop legs carrying spray nozzles in the region of their lower ends. The support elements extend downwardly between crop rows and are moved lengthwise of the crop rows while spraying proceeds. The spray nozzles deliver spray generally upwardly and/or horizontally with respect to the ground so as to treat crop material in the rows. The support elements are mounted so as to float freely and permit lateral movement to follow lateral and other row and crop contours. The support elements may be mounted on a boom. The boom may also be provided with downwardly directed spraying nozzles for simultaneous or sequential use. The boom is adapted to fold so as to produce a generally Z-shaped folded configuration. Automatically-actuated stop fingers limit lateral float of the support elements when the boom folds. For lodged crop, the spray nozzles on the support elements may be replaced by rotary wheel elements having projecting spoke elements which penetrate the crop and themselves carry spray nozzles to distribute spray from within the crop. A power driven air discharge nozzle may be provided to assist dispersal of the spray.
Patent AU-6225786-A (AU)
Title: Receptacle for blood
Inventor: LISS EBERHARD
IPC: G01N33/48
Filed: 1986-08-06
Abstract: PCT No. PCT/DE86/00320 Sec. 371 Date Mar. 30, 1987 Sec. 102(e) Date Mar. 30, 1987 PCT Filed Aug. 6, 1986 PCT Pub. No. WO87/00769 PCT Pub. Date Feb. 12, 1987.Inclusion in a blood sample of an isomer of glucose which is capable of replacing glucose in blood cell metabolism ensures accuracy of glucose assay.
Patent AU-6322699-A (AU)
Title: Closed extruded closure
Inventor: LAGLER LOUIS
IPC: B65D55/16
Filed: 1999-10-30
Abstract: A closed injection moulded plastic closure ( 20 ) having a first closure part and a second closure part ( 22 ). The first closure part is connected to the second closure part by snap-on hinged connection. The first and second closure parts have no main hinged connection with each other, but are connected to one another by two connecting elements and four hinged connections bordering the two connecting elements on nonadjacent sides. Coupling elements may serve as an original warranty seal for indicating opening for the first time. If required, a catch and a counter-element serve as a locking mechanism and prevent unintentional opening of the closure.
Patent AU-6510398-A (AU)
Title: Recoverable article
Inventor: IONS DAVID
IPC: H02G15/18
Filed: 1998-03-18
Abstract: A recoverable article comprising an inner resilient tubular member that is held out in a laterally expanded configuration by engagement with outer holdout structure, wherein the outer surface of the inner member is provided with a plurality of cavities, and wherein the holdout structure occupies the cavities so as to provide the holdout engagement, wherein the holdout structure comprises at least one initiating portion that is structurally different from the remaining portion that engages at least one associated cavity, whereby release of the initiating portion from its cavity facilitates subsequent release of the remaining portion of the holdout structure.
Patent AU-6733487-A (AU)
Title: Mammalian interleukin-4
Inventor: LEE FRANK
IPC: C12N15/11
Filed: 1986-11-19
Abstract: Antibodies to mammalian Interleukin-4 and muteins are provided, especially to native human IL-4s, as well as peptides useful as antigens in their production. Nucleic acids are disclosed which are capable of coding for the mammalian IL-4s and their muteins.
Patent AU-6752001-A (AU)
Title: Method and system for predicting therapeutic agent resistance and for defining the genetic basis of drug resistance using neural networks
Inventor: LARDER BRENDAN
IPC: G16H70/20
Filed: 2001-06-01
Abstract: A method and system for predicting the resistance of a disease to a therapeutic agent is provided. Further provided is a method and system for designing a therapeutic treatment agent for a patient afflicted with a disease. Specifically, the methods use a trained neural network to interpret genotypic information obtained from the disease. The trained neural network is trained using a database of known or determined genotypic mutations that are correlated with phenotypic therapeutic agent resistance. The present invention also provides methods and systems for predicting the probability of a patient developing a genetic disease. A trained neural network for making such predictions is also provided. Also provided is a method and system for determining the genetic basis of therapeutic agent resistance.
Patent AU-6966596-A (AU)
Title: Method for modulating cell apoptosis
Inventor: DAMME JO VAN
IPC: A61K38/00
Filed: 1996-09-04
Abstract: The invention is based upon the newly recognized ability of  beta chemokines to inhibit cell apoptosis. In particular, apoptosis of T cells is described. The known  beta  chemokines I-309 and TCA-3 are examples of the  beta  chemokines which inhibit apoptosis. One aspect of the invention is the use of these molecules to inhibit apoptosis. A second aspect of the invention is the use of  beta  chemokine inhibitors or antagonists to provoke apoptosis.
Patent AU-6989700-A (AU)
Title: Method, system and apparatus for proximity-based recharge notification
Inventor: HANSSON MAGNUS
IPC: H04M1/72412
Filed: 2000-07-31
Abstract: An apparatus, system and method notifies a user of a low battery condition when the remaining battery capacity of a portable electronic device, such as a mobile station, pager, portable computer, video camera, or personal digital assistant, falls below a predetermined level and the portable electronic device is proximally located to a corresponding charging unit. The proximity of the portable electronic device to the charging unit may be detected by using geographic positioning, such as the GPS, the GLONASS or the GSM location-determining algorithms, or by monitoring a short range radio interface, such as Bluetooth or Home RF.
Patent AU-7004900-A (AU)
Title: Adhesive protein foam for surgical and/or therapeutic uses
Inventor: TAYOT JEAN-LOUIS
IPC: A61P17/02
Filed: 2000-07-20
Abstract: A biocompatible fluid adhesive protein foam, which is bioresorbable and nontoxic, for surgical and/or therapeutic use, in particular for protecting/cicatrizing tissue wounds and for attaching biological tissues to each other or to an implanted biomaterial. The biocompatible fluid adhesive protein foam includes a biocompatible fluid adhesive protein matrix, which is bioresorbable and nontoxic, containing a biocompatible and nontoxic gas or mixture of gases. Further, a process and a kit for preparing such a foam are provided.
Patent AU-7023400-A (AU)
Title: Radar apparatus for imaging and/or spectrometric analysis and methods of performing imaging and/or spectrometric analysis of a substance for dimensional measurement, identification and precision radar mapping
Inventor: STOVE GEORGE COLIN
IPC: G01N22/00
Filed: 2000-09-07
Abstract: Radar apparatus and methods of use thereof for imaging and/or spectrometric analysis. The invention employs pulsed radar signals for magnifying, imaging, scale measuring, identifying and/or typecasting the composition of substances by radargrammetric imaging and/or statistical analysis of energy/frequency spectrs. The invention may be used to locate and/or distinguish a substance from other substances, to image a substance/feature and to monitor the movement of an imaged substance/feature. The systems and methods can be adapted for a variety of applications at a wide range of scales and distances, from large scale, long range applications such as geophysical imaging/analysis, to the small scale such as material typecasting applications and small scale (including microscopic) imaging/analysis, including biological and medical imaging and diagnostic applications. The invention includes novel antenna assemblies and novel data processing techniques.
Patent AU-7287891-A (AU)
Title: Novel ascorbic acid derivatives
Inventor: MARCINIAK GILBERT
IPC: A61K31/341
Filed: 1991-03-14
Abstract: This invention relates to derivatives of certain 3,4-dihydroxy-2,5-dihydrofuran-5-ones, to the intermediates and processes useful for their preparation, to their free-radical scavenger and cellular protective properties, and to their end-use application as therapeutic agents.
Patent AU-7462481-A (AU)
Title: Diphenylmethane polyisocyanates
Inventor: KNOFEL H
IPC: C08G18/76
Filed: 1981-08-26
Abstract: A polyisocyanate or mixture of polyisocyanates in which the main component(s) correspond to the formula:   <IMAGE>   in which R1, R2, and R3 each represent hydrogen or a saturated alkyl group containing from 1 to 12 carbon atoms, provided that at least two of these radicals represent hydrogen; and m, n, o and p each represent 0 or 1, provided that when m, n, o and/or p represent 0, the free valency is taken up by a hydrogen atom and that the sum of m+n+o+p is greater than 1 on a statistical average. Such polyisocyanate or mixture of polyisocyanates may be produced by first reacting a 4-nitrobenzyl halide, a 3-nitrobenzyl halide, a benzyl halide, a benzyl alcohol or a nitrobenzyl chloride isomer mixture with nitrobenzene, an alkyl-substituted nitrobenzene, an alkyl benzene or benzene in the presence of a Friedel-Crafts or an acid catalyst. This reaction product is then nitrated, the nitro groups are converted to amino groups by reduction or hydrogenation and the amino compound(s) subsequently phosgenated to form the polyisocyanate(s). The purity of the product polyisocyanate may be improved by distilling off secondary products before and/or after the phosgenation.
Patent AU-7584391-A (AU)
Title: Line interface circuit with active tip and ring feed means
Inventor: DAS TAPAN KUMAR
IPC: H04Q3/42
Filed: 1991-04-17
Abstract: A line interface circuit supplies energizing direct current from a power source via tip and ring leads of a two wire communications line connected with a telephone apparatus, and also couples alternating current signals between the telephone line and an associated telephone facility. The line interface circuit is provided with tip and ring terminals for connection to the tip and ring leads, and power terminals for connection to the power source. Coupling circuitry is connected in series with the tip and ring terminals for providing paths for the energizing direct current and for the alternating current signals. An active tip feed circuit is connected in series between the tip terminal and the coupling circuitry for providing a tip feed path having a predetermined resistance while the telephone apparatus is in an OFF HOOK state and having a much higher resistance in response to an excess of voltage at the tip terminal. An active ring feed circuit is connected in series between the ring terminal and the coupling circuitry for providing a ring feed path having a predetermined resistance while the telephone apparatus is in the OFF HOOK state and having a much higher resistance in response to an excess of voltage at the ring terminal.
Patent AU-7683296-A (AU)
Title: Peptide conjugates derived from thymic hormones, their use as medicament and compositions containing them
Inventor: HINTERLAND LUCIEN DUSSOURD D
IPC: A61K8/40
Filed: 1996-11-15
Abstract: The invention relates to peptide conjugates comprising a sequence of at least 3 amino acids derived from a thymic hormone selected amongst thymuline and thymopoietine, the amino acids being independently in the form D, L or DL, said sequence being chemically or physically conjugated with at least one compound selected amongst monocarboxylic acids having the general formula (I): HOOC-R, as well as alcohol, aldehyde or amide derivatives, the dicarboxylic acids having the general formula (II): HOOC-R1-COOH. The invention also relates to the use of such conjugates as medicaments, and pharmaceutical or cosmetological compositions containing them.
Patent AU-7727091-A (AU)
Title: Method for protecting dams, with pressureless dehydration by condensation and drainage of the water in the dam body
Inventor: SCUERO ALBERTO
IPC: E02B7/08
Filed: 1991-05-22
Abstract: A method and an assembly for protecting dams according to which dehydration of the dam body (10) is obtained as a result of the differences in temperature between the concrete structure (10) and a steam barrier defined by a water-proof protective sheathing (13). The condensation water and any seeping water is eliminated by means of a drainage channel system (14, 17) at atmospheric pressure. <IMAGE>
Patent AU-7750194-A (AU)
Title: Linear adhesion inhibitors
IPC: A61K38/08
Filed: 1994-10-26
Abstract: Linear peptides of the formula I  X-A-Cys(R<1>)-B-Z     I,  wherein A, B, R<1>, X and Z have the meaning indicated in Claim 1, are effective inhibitors of binding of the blood platelet integrin GP IIbIIIa (aIIbss3) to natural ligands and are suitable, inter alia, for the prophylaxis and the treatment of disorders of the circulation, in thrombosis, cardiac infarct, coronary heart disorders, arterio- and atherosclerosis, tumours, osteolytic disorders, and assist in wound healing processes.
Patent AU-7776701-A (AU)
Title: Skin wound healing promoters
Inventor: NISHIDA TERUO
IPC: A61K38/08
Filed: 2001-08-10
Abstract: The present invention provides healing promoters for skin wounds such as rupture, abrasion, surgical incision, skin ulcer and burn. Coexistence of Arg-Pro-Lys-Pro-Gln-Gln-Phe-Phe-Gly-Leu-Met-NH2 or Phe-Gly-Leu-Met-NH2 with insulin-like growth factor-I exhibits a remarkable promotive action on healing the skin wounds. Accordingly, combined administration of at least one of the substance P analogs and pharmaceutically acceptable salts thereof with the insulin-like growth factor exhibits a promotive effect on epidermal extension and a promotive effect on healing the skin wounds.
Patent AU-7952200-A (AU)
Title: Medicinal compositions for inhibiting gvhd
Inventor: KATAOKA MOTOYUKI
IPC: A61K38/19
Filed: 2000-10-20
Abstract: A method for effectively suppressing GVHD, which occurs after peripheral blood stem cells allotransplantation, without causing marked side effects, and a pharmaceutical composition intended for this purpose and containing human G-CSF as an active ingredient. GVHD can be suppressed by administering human G-CSF to a transplantation recipient after peripheral blood stem cells transplantation. <IMAGE>
Patent AU-8087791-A (AU)
Title: Colonic drug delivery system
Inventor: SINTOV AMNON
IPC: A61K47/36
Filed: 1991-05-02
Abstract: A colonic delivery system for delivering a drug to the colon is provided. The system comprises a drug in combination with a matrix, wherein the matrix comprises a saccharide-containing polymer. According to the invention, the matrix is resistant to chemical and enzymatic degradation in the stomach and small intestine. The matrix is degraded in the colon by bacterial enzymatic action, and the drug is released. The system is useful for targeting drugs to the colon in order to treat colonic disease. The system is also useful for enteric administration of drugs such as proteins and peptides which are otherwise degraded in the stomach and small intestine.
Patent AU-8182687-A (AU)
Title: A process for the preparation of aldehydes
Inventor: BACK HANSWILHELM
IPC: C07C45/50
Filed: 1987-11-26
Abstract: In a hydroformylation process for the preparation of aldehydes by reacting aliphatic olefins of 2 to 12 carbon atoms with carbon monoxide and hydrogen at temperatures of 20 DEG  to 150 DEG  C. and pressures of 0.1 to 20 mPa in the liquid phase and in the presence of an aqueous solution of a catalyst containing originally 50 to 800 wt. ppm of rhodium and 25 to 30 wt. % of complex-forming, sulfonated or carboxylated triarylphosphines, in each case based on the aqueous solution, the improvement comprising adding fresh phosphine solution to maintain the original phosphine concentration, until the total concentration of complex-forming phosphines and secondary and degradation products of the phosphines not capable of forming complexes amounts to about 35 to 45 wt. % based on the aqueous solution to selectively form n-aldehydes.
Patent AU-8339098-A (AU)
Title: Electrochromic polymer systems
Inventor: BERNETH HORST
IPC: G02F1/1503
Filed: 1998-06-24
Abstract: Electrochromic systems containing soluble electrochromic polymers which are accessible by polymerization, polycondensation or polyaddition from electrochromic monomers are used in devices for variable transparency to electromagnetic radiation.